REFERENCES
1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-25.
2. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395-406.
3. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-54.
4. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011-24.
5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33.
6. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-21.
7. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
8. Gordon-Dseagu VL, Devesa SS, Goggins M, Stolzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the surveillance, epidemiology and end results (SEER) population-based data. Int J Epidemiol. 2018;47:427-39.
9. Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153-71.
10. Holly EA, Chaliha I, Bracci PM, Gautam M. Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. Clin Gastroenterol Hepatol. 2004;2:510-7.
12. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB. 2008;10:371-6.
13. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-77.
14. Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized preopanc trial. J Clin Oncol. 2022;40:1220-30.
15. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III preopanc trial. J Clin Oncol. 2020;38:1763-73.
16. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-703.
17. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
18. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65.
19. O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1431-8.
20. Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res. 2018;24:1326-36.
21. Humphris JL, Patch AM, Nones K, et al. Hypermutation in pancreatic cancer. Gastroenterology. 2017;152:68-74.e2.
22. Bian J, Almhanna K. Pancreatic cancer and immune checkpoint inhibitors-still a long way to go. Transl Gastroenterol Hepatol. 2021;6:6.
23. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418-29.
24. Truong LH, Pauklin S. Pancreatic cancer microenvironment and cellular composition: current understandings and therapeutic approaches. Cancers. 2021;13:5028.
26. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-6.
28. Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33:3124-9.
29. Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35:3382-90.
30. O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 2020;38:1378-88.
31. Fogelman D, Sugar EA, Oliver G, et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015;76:489-98.
32. Reiss KA, Yu S, Judy R, Symecko H, Nathanson KL, Domchek SM. Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations. JCO Precis Oncol. 2018;2:1-9.
33. Yu S, Agarwal P, Mamtani R, et al. Retrospective survival analysis of patients with resected pancreatic ductal adenocarcinoma and a germline BRCA or PALB2 mutation. JCO Precis Oncol. 2019;3:1-11.
34. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-27.
35. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47-52.
36. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500-3.
37. Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168-78.
38. Topham JT, Karasinska JM, Lee MKC, et al. Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics. Clin Cancer Res. 2021;27:150-7.
39. Hayashi A, Fan J, Chen R, et al. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nat Cancer. 2020;1:59-74.
40. Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52:231-40.
41. Raghavan S, Winter PS, Navia AW, et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021;184:6119-6137.e26.
42. Porter RL, Magnus NK, Thapar V, Morris R, Szabolcs A, Neyaz A, Kulkarni AS, Tai E, Chougule A, Hillis A. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2019;116:26835-45.
43. Madura JA, Jarman BT, Doherty MG, Yum MN, Howard TJ. Adenosquamous carcinoma of the pancreas. Arch Surg. 1999;134:599-603.
44. Board WCoTE. Digestive system tumors. Lyon, France; 2019.
45. Kardon DE, Thompson LD, Przygodzki RM, Heffess CS. Adenosquamous carcinoma of the pancreas: a clinicopathologic series of 25 cases. Mod Pathol. 2001;14:443-51.
46. Murakami Y, Yokoyama T, Yokoyama Y, et al. Adenosquamous carcinoma of the pancreas: preoperative diagnosis and molecular alterations. J Gastroenterol. 2003;38:1171-5.
47. Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16:207-20.
48. Olson MT, Siddiqui MT, Ali SZ. The differential diagnosis of squamous cells in pancreatic aspirates: from contamination to adenosquamous carcinoma. Acta Cytol. 2013;57:139-46.
49. Voong KR, Davison J, Pawlik TM, et al. Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol. 2010;41:113-22.
50. Ito T, Sugiura T, Okamura Y, et al. Long-term outcomes after an aggressive resection of adenosquamous carcinoma of the pancreas. Surg Today. 2019;49:809-19.
51. Lee SM, Sung CO. PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions. Pancreatology. 2021;21:920-7.
52. Viswanathan K, Rao R. Pancreatic ductal adenocarcinoma and its variants. In: Pancreas and biliary tract cytohistology. Cham: Springer International Publishing; 2019. pp. 95-145.
53. Brody JR, Costantino CL, Potoczek M, et al. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol. 2009;22:651-9.
54. Taniwaki S, Hisaka T, Sakai H, et al. Sarcomatous component in pancreatic adenosquamous carcinoma: a clinicopathological series of 7 cases. Anticancer Res. 2019;39:4575-80.
55. Boecker W, Tiemann K, Boecker J, et al. Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas: evidence supporting the squamous metaplasia concept. Histochem Cell Biol. 2020;154:97-105.
56. Lu BC, Wang C, Yu JH, Shen ZH, Yang JH. A huge adenosquamous carcinoma of the pancreas with sarcomatoid change: an unusual case report. World J Gastroenterol. 2014;20:16381-6.
57. Silvestris N, Brunetti O, Pinto R, et al. Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. Expert Opin Ther Targets. 2018;22:453-61.
58. Tanigawa M, Naito Y, Akiba J, et al. PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component. Pathol Res Pract. 2018;214:2069-74.
59. Motojima K, Tomioka T, Kohara N, Tsunoda T, Kanematsu T. Immunohistochemical characteristics of adenosquamous carcinoma of the pancreas. J Surg Oncol. 1992;49:58-62.
60. Borazanci E, Millis SZ, Korn R, et al. Adenosquamous carcinoma of the pancreas: molecular characterization of 23 patients along with a literature review. World J Gastrointest Oncol. 2015;7:132-40.
61. Fang Y, Su Z, Xie J, et al. Genomic signatures of pancreatic adenosquamous carcinoma (PASC). J Pathol. 2017;243:155-9.
62. Lenkiewicz E, Malasi S, Hogenson TL, et al. Genomic and epigenomic landscaping defines new therapeutic targets for adenosquamous carcinoma of the pancreas. Cancer Res. 2020;80:4324-34.
63. Matsuzaka S, Karasaki H, Ono Y, et al. Tracking the clonal evolution of adenosquamous carcinoma, a rare variant of intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 2016;45:915-8.
64. Liu C, Karam R, Zhou Y, et al. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nat Med. 2014;20:596-8.
65. Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.
66. Polaski JT, Udy DB, Escobar-Hoyos LF, et al. The origins and consequences of UPF1 variants in pancreatic adenosquamous carcinoma. Elife. 2021;2021:10.
67. Dey P, Li J, Zhang J, et al. Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment. Cancer Discov. 2020;10:608-25.
68. Maddipati R, Norgard RJ, Baslan T, et al. MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. Cancer Discov. 2022;12:542-61.
69. Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, et al. Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 2020;10:872-87.
70. Shukla SK, Gunda V, Abrego J, et al. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget. 2015;6:19118-31.
71. Karasinska JM, Topham JT, Kalloger SE, et al. Altered gene expression along the glycolysis-cholesterol synthesis axis is associated with outcome in pancreatic cancer. Clin Cancer Res. 2020;26:135-46.
72. Somerville TDD, Xu Y, Miyabayashi K, et al. TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma. Cell Rep. 2018;25:1741-1755.e7.
73. Hamdan FH, Johnsen SA. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network. Proc Natl Acad Sci USA. 2018;115:E12343-52.
74. Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W, Tzatsos A. Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. Cancer Cell. 2018;33:512-526.e8.
75. Kalisz M, Bernardo E, Beucher A, et al. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer. EMBO J. 2020;39:e102808.
76. Kloesch B, Ionasz V, Paliwal S, et al. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Gut. 2022;71:766-77.
77. Imaoka H, Shimizu Y, Mizuno N, et al. Clinical characteristics of adenosquamous carcinoma of the pancreas: a matched case-control study. Pancreas. 2014;43:287-90.
78. Kaiser J, Hinz U, Mayer P, et al. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2021;47:1734-41.
79. Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS. 415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival. J Surg Res. 2012;174:12-9.
80. Hester CA, Augustine MM, Choti MA, et al. Comparative outcomes of adenosquamous carcinoma of the pancreas: an analysis of the National Cancer Database. J Surg Oncol. 2018;118:21-30.
81. Katz MH, Taylor TH, Al-Refaie WB, et al. Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis. J Gastrointest Surg. 2011;15:165-74.
82. Yang Z, Shi G, Zhang P. Development and validation of nomograms to predict overall survival and cancer-specific survival in patients with pancreatic adenosquamous carcinoma. Front Oncol. 2022;12:831649.
83. Yoshida Y, Kobayashi S, Ueno M, et al. Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: a multicenter retrospective analysis. Pancreatology. 2022;22:1159-66.
84. Lozano MD, Panizo A, Sola IJ, Pardo-Mindán FJ. FNAC guided by computed tomography in the diagnosis of primary pancreatic adenosquamous carcinoma: a report of three cases. Acta Cytol. 1998;42:1451-4.
85. Toshima F, Inoue D, Yoshida K, et al. Adenosquamous carcinoma of pancreas: CT and MR imaging features in eight patients, with pathologic correlations and comparison with adenocarcinoma of pancreas. Abdom Radiol. 2016;41:508-20.
86. Feng YF, Chen JY, Chen HY, et al. 110 patients with adenosquamous carcinomas of the pancreas (PASC): imaging differentiation of small (≤ 3 cm) versus large (> 3 cm) tumors. Abdom Radiol. 2019;44:2466-73.
87. Zhao R, Jia Z, Chen X, et al. CT and MR imaging features of pancreatic adenosquamous carcinoma and their correlation with prognosis. Abdom Radiol. 2019;44:2822-34.
88. Schawkat K, Tsai LL, Jaramillo-Cardoso A, et al. Use of ring-enhancement and focal necrosis to differentiate pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma on CT and MRI. Clin Imaging. 2021;73:134-8.
89. Ren S, Zhao R, Cui W, et al. Computed tomography-based radiomics signature for the preoperative differentiation of pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma. Front Oncol. 2020;10:1618.
90. Arco H, Chakiba-Brugère C, Salabert L, Béchade D. Adenosquamous carcinoma of the pancreas. Clin Med Insights Oncol. 2019;13:1179554919886587.
91. Inomata N, Masuda A, Itani T, et al. An autopsy case of granulocyte colony-stimulating factor-producing pancreatic adenosquamous carcinoma. Clin J Gastroenterol. 2020;13:448-54.
92. Skafida E, Grammatoglou X, Glava C, et al. Adenosquamous carcinoma of the pancreas: a case report. Cases J. 2010;3:41.
93. Na YJ, Shim KN, Cho MS, et al. Primary adenosquamous cell carcinoma of the pancreas: a case report with a review of the Korean literature. Korean J Intern Med. 2011;26:348-51.
94. Kelly K, Moore C. Two rare cases of pancreatic adenosquamous carcinoma: a review of the literature with focus on radiologic findings. Radiol Case Rep. 2019;14:809-13.
95. Nabae T, Yamaguchi K, Takahata S, et al. Adenosquamous carcinoma of the pancreas: report of two cases. Am J Gastroenterol. 1998;93:1167-70.
96. Kurdi YM, Peck JR, Roth R, Conwell DL. A case of pancreatic adenosquamous carcinoma obstructing the common bile and pancreatic ducts, duodenum, and gastric outlet. Pancreas. 2016;45:e9-e10.
97. López-Tomassetti-Fernández EM, Favre-Rizzo J, Delgado-Plasencia L, Hernández-Hernández JR. Hypercalcemia associated with adenosquamous pancreatic carcinoma: a reason to initiate palliative treatment. Rev Esp Enferm Dig. 2013;105:425-8.
98. Kobayashi N, Higurashi T, Iida H, et al. Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). J Hepatobiliary Pancreat Surg. 2008;15:531-5.
99. Inoue T, Nagao S, Tajima H, et al. Adenosquamous pancreatic cancer producing parathyroid hormone-related protein. J Gastroenterol. 2004;39:176-80.
100. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373-9.
101. Wild AT, Dholakia AS, Fan KY, et al. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. J Gastrointest Oncol. 2015;6:115-25.
102. Hue JJ, Katayama E, Sugumar K, et al. The importance of multimodal therapy in the management of nonmetastatic adenosquamous carcinoma of the pancreas: analysis of treatment sequence and strategy. Surgery. 2021;169:1102-9.
103. Altman AM, Wirth K, Marmor S, et al. Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival. Ann Surg Oncol. 2019;26:4108-16.
104. DePeralta DK, Ogami T, Zhou JM, et al. Completion of adjuvant therapy in patients with resected pancreatic cancer. HPB. 2020;22:241-8.
105. Romano E, Janati S, Monnier L, et al. Outcomes of vaginal squamous cell carcinoma of patients treated with radiation therapy: a series of 37 patients from a single expert center. Clin Transl Oncol. 2020;22:1345-54.
106. Maubec E. Update of the management of cutaneous squamous-cell carcinoma. Acta Derm Venereol. 2020;100:adv00143.
107. Mendenhall WM, Strojan P, Lee AWM, et al. Radiotherapy in the management of glottic squamous cell carcinoma. Head Neck. 2020;42:3558-67.
108. Lin HN, Chen LQ, Shang QX, Yuan Y, Yang YS. A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma. Int J Surg. 2020;80:184-91.
109. Yamaue H, Tanimura H, Onishi H, et al. Adenosquamous carcinoma of the pancreas: successful treatment with extended radical surgery, intraoperative radiation therapy, and locoregional chemotherapy. Int J Pancreatol. 2001;29:53-8.
110. Hsu JT, Yeh CN, Chen YR, et al. Adenosquamous carcinoma of the pancreas. Digestion. 2005;72:104-8.
111. Brunetti O, Aprile G, Marchetti P, et al. Systemic chemotherapy for advanced rare pancreatic histotype tumors: a retrospective multicenter analysis. Pancreas. 2018;47:759-71.
112. Tanaka N, Ohoida J, Matuno T, et al. Response of adenosquamous carcinoma of the pancreas to interferon-alpha, tumor necrosis factor-alpha and 5-fluorouracil combined treatment. Anticancer Res. 1994;14:2739-42.
113. Noel P, Hussein S, Ng S, et al. Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. Oncogenesis. 2020;9:100.
114. Skorupan N, Ahmad MI, Steinberg SM, et al. A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas. Future Oncol. 2022;18:2475-81.
115. Klimstra DS, Heffess CS, Oertel JE, Rosai J. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16:815-37.
116. Toll AD, Hruban RH, Ali SZ. Acinar cell carcinoma of the pancreas: clinical and cytomorphologic characteristics. Korean J Pathol. 2013;47:93-9.
117. Klimstra DS, Rosai J, Heffess CS. Mixed acinar-endocrine carcinomas of the pancreas. Am J Surg Pathol. 1994;18:765-78.
118. Abraham SC, Wu TT, Hruban RH, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol. 2002;160:953-62.
119. Klimstra DS, Adsay V. Acinar neoplasms of the pancreas-A summary of 25 years of research. Semin Diagn Pathol. 2016;33:307-18.
120. Thompson ED, Wood LD. Pancreatic neoplasms with acinar differentiation: a review of pathologic and molecular features. Arch Pathol Lab Med. 2020;144:808-15.
121. La Rosa S, Franzi F, Marchet S, et al. The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch. 2009;454:133-42.
122. Hosoda W, Sasaki E, Murakami Y, Yamao K, Shimizu Y, Yatabe Y. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. Pathol Int. 2013;63:176-82.
123. Said S, Kurtin PJ, Nasr SH, et al. Carboxypeptidase A1 and regenerating islet-derived 1α as new markers for pancreatic acinar cell carcinoma. Hum Pathol. 2020;103:120-6.
124. Uhlig R, Contreras H, Weidemann S, et al. Carboxypeptidase A1 (CPA1) immunohistochemistry is highly sensitive and specific for acinar cell carcinoma (ACC) of the pancreas. Am J Surg Pathol. 2022;46:97-104.
125. Jiao Y, Yonescu R, Offerhaus GJ, et al. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol. 2014;232:428-35.
126. Chmielecki J, Hutchinson KE, Frampton GM, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov. 2014;4:1398-405.
127. Jäkel C, Bergmann F, Toth R, et al. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. Nat Commun. 2017;8:1323.
128. Furukawa T, Sakamoto H, Takeuchi S, et al. Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. Sci Rep. 2015;5:8829.
129. Chou A, Kim Y, Samra JS, Pajic M, Gill AJ. BRAF gene rearrangements can be identified by FISH studies in pancreatic acinar cell carcinoma. Pathology. 2018;50:345-8.
130. Prall OWJ, Nastevski V, Xu H, et al. RAF1 rearrangements are common in pancreatic acinar cell carcinomas. Mod Pathol. 2020;33:1811-21.
131. Chou A, Brown IS, Kumarasinghe MP, et al. RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas. Mod Pathol. 2020;33:657-64.
132. Gupta M, Sherrow C, Krone ME, et al. Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: a case report and review of the literature. J Natl Compr Canc Netw. 2021;19:10-5.
133. Liu W, Shia J, Gönen M, Lowery MA, O’Reilly EM, Klimstra DS. DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance. Pancreas. 2014;43:1264-70.
134. Kryklyva V, Haj Mohammad N, Morsink FHM, et al. Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review. Cancer Biol Ther. 2019;20:949-55.
135. Lee JH, Park SJ, Hariharasudhan G, et al. ID3 regulates the MDC1-mediated DNA damage response in order to maintain genome stability. Nat Commun. 2017;8:903.
136. Bakr A, Hey J, Sigismondo G, et al. ID3 promotes homologous recombination via non-transcriptional and transcriptional mechanisms and its loss confers sensitivity to PARP inhibition. Nucleic Acids Res. 2021;49:11666-89.
137. Xu J, Palestino Dominguez M, Alewine C. Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci. Cancer Commun. 2022;42:269-72.
138. La Rosa S, Bernasconi B, Frattini M, et al. TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. Virchows Arch. 2016;468:289-96.
139. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic cancer registry in japan: 20 years of experience. Pancreas. 2004;28:219-30.
140. Mustafa S, Hruban RH, Ali SZ. Acinar cell carcinoma of the pancreas: a clinicopathologic and cytomorphologic review. J Am Soc Cytopathol. 2020;9:586-95.
141. Sridharan V, Mino-Kenudson M, Cleary JM, et al. Pancreatic acinar cell carcinoma: a multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021:1119-26.
142. Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008;12:2078-86.
143. Petrova E, Wellner J, Nording AK, et al. Survival outcome and prognostic factors for pancreatic acinar cell carcinoma: retrospective analysis from the german cancer registry group. Cancers. 2021;13:6121.
144. Duorui N, Shi B, Zhang T, et al. The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: a population-based study. PLoS One. 2020;15:e0243164.
145. Wisnoski NC, Townsend CM Jr, Nealon WH, Freeman JL, Riall TS. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery. 2008;144:141-8.
146. Seo S, Yoo C, Kim KP, et al. Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma. J Dig Dis. 2017;18:480-6.
147. Shin SH, Hwang HK, Jang JY, et al. Clinical characteristics of resected acinar cell carcinoma of the pancreas: a korean multi-institutional study. Cancers. 2021;13:5095.
148. Huang X, Li M, Zhang L, Xiong J, Lu H, Tian B. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: a single institutional comparison to pancreatic ductal adenocarcinoma. Surg Oncol. 2021;37:101528.
149. Seket B, Saurin JC, Scoazec JY, Partensky C. [Pancreatic acinar cell carcinoma in a patient with familial adenomatous polyposis]. Gastroenterol Clin Biol. 2003;27:818-20.
150. Karamurzin Y, Zeng Z, Stadler ZK, et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol. 2012;43:1677-87.
151. Li M, Mou Y, Hou S, Cao D, Li A. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: a case report. Medicine. 2018;97:e13113.
152. Labate AM, Klimstra DL, Zakowski MF. Comparative cytologic features of pancreatic acinar cell carcinoma and islet cell tumor. Diagn Cytopathol. 1997;16:112-6.
153. Stelow EB, Bardales RH, Shami VM, et al. Cytology of pancreatic acinar cell carcinoma. Diagn Cytopathol. 2006;34:367-72.
154. Tharian B, Canipe AL, Krall K, Hawes RH, Hébert-Magee S. Ring around the ROSE: pancreatic acinar cell carcinoma diagnosed on site by EUS-FNA. Gastrointest Endosc. 2015;81:1049-50.
155. Toyonaga Y, Yamazaki K, Yamada M, Koyasu T, Koyama Y, Ishida Y. Brush cytology of acinar cell carcinoma of the pancreas with intraductal growth: a case report. Diagn Cytopathol. 2014;42:321-4.
156. Peng HQ, Darwin P, Papadimitriou JC, Drachenberg CB. Liver metastases of pancreatic acinar cell carcinoma with marked nuclear atypia and pleomorphism diagnosed by EUS FNA cytology: a case report with emphasis on FNA cytological findings. Cytojournal. 2006;3:29.
157. Barat M, Dohan A, Gaujoux S, et al. Computed tomography features of acinar cell carcinoma of the pancreas. Diagn Interv Imaging. 2020;101:565-75.
158. Jornet D, Soyer P, Terris B, et al. MR imaging features of pancreatic acinar cell carcinoma. Diagn Interv Imaging. 2019;100:427-35.
159. Matos JM, Schmidt CM, Turrini O, et al. Pancreatic acinar cell carcinoma: a multi-institutional study. J Gastrointest Surg. 2009;13:1495-502.
160. Singh S, Gorouhi F, Konia T, Burrall B. Pancreatic acinar cell carcinoma-induced panniculitis. JAAD Case Rep. 2018;4:719-21.
161. Nizam W, Shah AA, Rajack F, Ramdath A, Naab T, Williams M. Lipase hypersecretion syndrome: a rare cutaneous manifestation of advanced pancreatic acinar cell carcinoma. Clin Case Rep. 2020;8:905-10.
162. Good AE, Schnitzer B, Kawanishi H, Demetropoulos KC, Rapp R. Acinar pancreatic tumor with metastatic fat necrosis: report of a case and review of rheumatic manifestations. Am J Dig Dis. 1976;21:978-87.
163. Burns WA, Matthews MJ, Hamosh M, Vander Weide G, Blum R, Johnson FB. Lipase-secreting acinar cell carcinoma of the pancreas with polyarthropathy.A light and electron microscopic, histochemical, and biochemical study. Cancer. 1974;33:1002-9.
164. Taskin OC, Adsay V. Lipase hypersecretion syndrome: a distinct form of paraneoplastic syndrome specific to pancreatic acinar carcinomas. Semin Diagn Pathol. 2019;36:240-5.
165. Askan G, Deshpande V, Klimstra DS, et al. Expression of markers of hepatocellular differentiation in pancreatic acinar cell neoplasms: a potential diagnostic pitfall. Am J Clin Pathol. 2016;146:163-9.
166. Patel DJ, Lutfi W, Sweigert P, et al. Clinically resectable acinar cell carcinoma of the pancreas: is there a benefit to adjuvant systemic therapy? Am J Surg. 2020;219:522-6.
167. Landa K, Freischlag K, Nussbaum DP, Youngwirth LM, Blazer DG 3rd. Underutilization of surgical resection in patients with pancreatic acinar cell carcinoma. HPB. 2019;21:687-94.
168. Burchard PR, Chacon AC, Melucci A, et al. Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma. J Surg Oncol. 2022;125:856-64.
169. Yoo C, Kim BJ, Kim KP, et al. Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: potentially improved efficacy with oxaliplatin-containing regimen. Cancer Res Treat. 2017;49:759-65.
170. Hiyoshi M, Kai K, Hamada T, Yano K, Imamura N, Nanashima A. Curative remnant total pancreatectomy for recurrent pancreatic acinar cell carcinoma: a case report. Int J Surg Case Rep. 2022;94:107091.
171. Ohara Y, Oda T, Enomoto T, et al. Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report. World J Surg Oncol. 2018;16:158.
172. Di Marco M, Carloni R, De Lorenzo S, et al. Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: a case report. World J Clin Cases. 2020;8:1241-50.
173. Sumiyoshi T, Shima Y, Okabayashi T, et al. Long-term survival following pancreatectomy and s-1 chemotherapy for pancreatic acinar cell carcinoma with peritoneal dissemination: a case report and literature review. Medicine. 2015;94:e378.
174. Cananzi FC, Jayanth A, Lorenzi B, et al. “Chronic” metastatic pancreatic acinar cell carcinoma. Pancreatology. 2013;13:549-52.
175. Jauch SF, Morris VK, Jensen CT, Kaseb AO. Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: a case report. Pancreatology. 2016;16:153-6.
176. Jimbo M, Batista PM, Baliff JP, Yeo CJ. Neoadjuvant chemotherapy and appleby procedure for pancreatic acinar cell carcinoma: a case report. Case Rep Pancreat Cancer. 2016;2:46-9.
177. Takahashi H, Ikeda M, Shiba S, et al. Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas. 2021;50:77-82.
178. Xu JY, Guan WL, Lu SX, et al. Optimizing chemotherapy of pancreatic acinar cell carcinoma: our experiences and pooled analysis of literature. Clin Med Insights Oncol. 2022;16:11795549221090186.
179. Lowery MA, Klimstra DS, Shia J, et al. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist. 2011;16:1714-20.
180. Schempf U, Sipos B, König C, Malek NP, Bitzer M, Plentz RR. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report. Z Gastroenterol. 2014;52:200-3.
181. Hashimoto M, Hikichi T, Suzuki T, et al. Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma. Clin J Gastroenterol. 2017;10:564-9.
182. Busch E, Kreutzfeldt S, Agaimy A, et al. Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma. Cold Spring Harb Mol Case Stud. 2020;6:a005553.
183. Cramer S, Marcus MA, Ramkissoon S, Szabo S, Pressey JG. Pediatric BRAF (V600E)-mutated pancreatic acinar cell carcinoma with complete and durable response to dabrafenib and trametinib. JCO Precis Oncol. 2020;4:801-5.
184. Gaule M, Pesoni C, Quinzii A, et al. Exceptional clinical response to alectinib in pancreatic acinar cell carcinoma with a novel ALK-KANK4 gene fusion. JCO Precis Oncol. 2022;6:e2100400.
185. Maehira H, Iida H, Mori H, et al. Pathological complete response in a patient with metastatic pancreatic acinar cell carcinoma who received a chemotherapy regimen containing cisplatin and irinotecan. Clin J Gastroenterol. 2021;14:1772-8.
186. Qin L, Shen J, Yang Y, Zou Z. Rapid response to the combination of lenvatinib and sintilimab in a pancreatic acinar cell carcinoma patient with elevated alpha-fetoprotein: a case report. Front Oncol. 2021;11:692480.
187. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-905.
188. Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:711-8.
189. Tiriac H, Belleau P, Engle DD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8:1112-29.
